|Articles|September 9, 2022
- Pharmaceutical Executive-09-01-2022
- Volume 42
- Issue 9
Pharmaceutical Executive, September 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
ESG: Applying Lessons From Consumer Marketover 3 years ago
21st Annual Industry Audit: Pharma Performance Checkover 3 years ago
The Manufacturing Edge on Path to Marketover 3 years ago
How Good is a Good Product Launch?over 3 years ago
More Than a Name: Vyvgartover 3 years ago
Fighting Vision Loss: Vabysmoover 3 years ago
A Sleeping Giant?: Quviviqover 3 years ago
Next-level Efficacy: MounjaroAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Datroway for Patients with Metastatic Triple-Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Candidates
2
What Kinds of Disruption are GLP-1s Expected to Face
3
Eli Lilly and Novo Nordisk Shift Patients From Compounded Drugs to Lower-Cost Weight-Loss Pills: Report
4
The Evolving Relationship Between FDA and Biotech
5